Singulair (Montelukast Sodium)

Singulair is indicated as additive therapy in patients with mild to moderate persistent asthma inadequately controlled on inhaled corticosteroids and in whom beta-2-agonists in the immediate short-term action and administered “on demand” does not provide a clinical control sufficient of asthma. For these patients, in whom Singulair is indicated for asthma, Singulair can simultaneously provide symptomatic relief of seasonal allergic rhinitis.

Singulair is also indicated in the prophylaxis of asthma induced by exercise.

In adults and adolescents 15 years and older, asthma, with or without seasonal allergic rhinitis associated with the recommended dosage is one 10 mg tablet daily in the evening.

General recommendations: the therapeutic effect of Singulair 10 mg on symptoms of asthma control occurs within one day. Singulair 10 mg can be taken with or without food.

Inform patients that they should continue their treatment even if the asthma is under control, as well as during periods of worsening symptoms. Singulair should not be used concomitantly with other products containing the same active ingredient (montelukast).

No dosage adjustment is necessary in elderly patients, patients with renal impairment or mild to moderate hepatic impairment. There are no data in patients with severe hepatic impairment.

The dosage is the same regardless of the sex of the patient is.

Administration of Singulair with other treatments for asthma

This medication may be associated with the ongoing treatment of asthma.

Inhaled corticosteroid: Singulair can be added to existing therapy when inhaled corticosteroids and the use of short duration of action “on demand” for the treatment of symptoms does not provide sufficient control of symptoms. Treatment Singulair should not be a substitute for inhaled corticosteroids (see section Warnings and Precautions.).

In children aged 6 to 14 years of chewable tablets 5 mg are available.